May 2 (Reuters) - AstraZeneca ( AZN ) said on Friday its

triple-combination inhaler Breztri Aerosphere met all main goals

in two late-stage trials for uncontrolled asthma, showing

clinically meaningful improvement in lung function.

The Anglo-Swedish drugmaker's therapy, already approved for

the treatment of Chronic Obstructive Pulmonary Disease or

"smoker's lung", was being compared with a dual-combination

maintenance treatment in the trials.

The results come as AstraZeneca ( AZN ) targets $80 billion in

revenue by 2030, after first-quarter sales this week missed

expectations on weaker oncology drug performance.

Asthma is a common but chronic lung disease that makes

breathing difficult due to inflammation and muscle tightening.

It affected 262 million people and caused 455,000 deaths in

2019, according to the World Health Organization.

"The results from the ... trials are exciting and

demonstrate the potential of

budesonide/glycopyrronium/formoterol to evolve the standard of

care to more effectively treat asthma in a single inhaled triple

therapy," said Alberto Papi, primary investigator of the

studies, referring to the compounds in Breztri Aerosphere.

AstraZeneca ( AZN ) said on Friday it would share detailed results

from the trials with authorities and seek to broaden approvals

for Breztri, which brought in sales of $978 million last year

and competes with GSK's Trelegy Ellipta.